Just some of the things that happened over the last 6

New Post Public Reply Private Reply Replies (0) Message Board

May 3, 2022 at 7:39 PM 355

Just some of the things that happened over the last 6 months. The rest you don't know about. Pretty impressive for a small company, but some should have invested in savings bonds as OTC is clearly not for them.

You should see the list of the next 6 months, first of which is Q1 results coming mid May.

May 02, 2022 10:02am EDT
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim

Apr 27, 2022 9:49am EDT
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022

Apr 25, 2022 10:51am EDT
Todos Medical to Present at the Emerging Growth Conference

Apr 21, 2022 7:59am EDT
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics

Apr 20, 2022 8:01am EDT
Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study

Apr 19, 2022 7:22am EDT
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group

Apr 06, 2022 8:46am EDT
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label

Apr 04, 2022 9:11am EDT
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants

Apr 01, 2022 2:17pm EDT
Update: Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates

Apr 01, 2022 11:29am EDT
Todos Medical Reports Fourth-Quarter and Full-Year 2021 Financial Results and Corporate Updates

Mar 31, 2022 11:17am EDT
Todos Medical Reports Case Study of Patient with Long COVID

Mar 28, 2022 8:21am EDT
Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products

Mar 17, 2022 7:00am EDT
Todos Medical to Present at the Proactive One2One Virtual Forum

Mar 16, 2022 7:00am EDT
Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma

Mar 15, 2022 7:00am EDT
Todos Medical to Present at the Emerging Growth Conference

Mar 08, 2022 9:53am EST
Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs

Jan 27, 2022 8:23am EST
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients

Jan 24, 2022 8:34am EST
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients

Jan 19, 2022 8:00am EST
Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical’s Tollovid®

Jan 18, 2022 10:52am EST
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies

Jan 12, 2022 9:56am EST
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022

Jan 10, 2022 2:06pm EST
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022

Jan 05, 2022 6:04pm EST
Todos Medical CEO Provides Letter to Shareholders

Jan 03, 2022 8:30am EST
Todos Medical to Present at January 5, 2022 Emerging Growth Conference

Dec 27, 2021 9:01am EST
Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista

Dec 23, 2021 7:37am EST
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing

Dec 22, 2021 9:56am EST
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States

Dec 20, 2021 7:30am EST
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing

Dec 17, 2021 8:51am EST
Todos Medical Announces “Test & Tollovid®” Holiday Package for Atlanta Area at Provista Diagnostics

Dec 16, 2021 12:25pm EST
Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19

Dec 13, 2021 7:30am EST
Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes

Dec 10, 2021 12:29pm EST
Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST

Dec 07, 2021 9:19am EST
Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics

Dec 06, 2021 3:14pm EST
Todos Medical to Present at Upcoming Emerging Growth Conference

Dec 02, 2021 6:00am EST
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation

Dec 01, 2021 4:05pm EST
Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST

Nov 30, 2021 8:38am EST
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant

Nov 29, 2021 9:08am EST
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma

Nov 24, 2021 2:00am EST
Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid® Products Covering 30 Countries in Europe

Nov 22, 2021 8:26am EST
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece

Nov 19, 2021 7:30am EST
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients

Nov 18, 2021 6:00am EST
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe

Nov 17, 2021 6:02pm EST
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test

Nov 16, 2021 1:18pm EST
Update: Todos Medical Reports Third Quarter 2021 Business and Financial Results

Nov 16, 2021 9:55am EST
Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests

Nov 15, 2021 7:18pm EST
Todos Medical Reports Third Quarter 2021 Business and Financial Results

Nov 02, 2021 9:05am EDT
Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place

Nov 01, 2021 7:35am EDT
Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients

Todos Med Ltd. (TOMDF) Stock Research Links

TOMDF Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Lunit, Summit Tackle Tumor Analysis with AI Platform

Amid whispers of AI revolutionizing every industry, let's zero in on its latest pit stop—oncology R&D. Lunit, shaking hands with Summit Therapeutics, plans to bring artificial intelligence into the tumor microenvironment analysis game, thanks to the Lunit SCOPE IO platform. This isn't just another lab experiment; it's a step towards redefining how we understand cancer's...

Darden Faces Class Action Over Reimbursement Failures

Class Action Puts Darden Restaurants in Legal Hot Seat Darden Restaurants, Inc. is staring down the barrel of a lawsuit that's as fiery as a grill on a Saturday night rush. The legal cavalry from Blumenthal Nordrehaug Bhowmik De Blouw LLP has stormed in with a class action complaint, aiming dead center at Darden for allegedly breaching the California Labor Code. In plain...

Millrose Faces Securities Fraud Suit Amidst Decline

Dark Clouds Over Millrose Properties Holy smokes, folks, if Millrose Properties thought it could skirt under the radar, they were dead wrong. The curtain's been peeled back, and what do we see? A mess of securities fraud allegations and financial hiccups that’s driving its shareholders mad. October wasn’t too friendly—Hunterbrook Media dropped a bombshell revealing...

Aluminum Design Fumble: Geometry Over Wall Thickness

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Hims & Hers Faces Securities Lawsuit Amid Stock Dive

Hims & Hers Takes a Hit Right out of the gate, we're seeing Hims & Hers Health, Inc. (NYSE:HIMS) embroiled in a securities class action, thanks to some good old-fashioned alleged corporate shenanigans. It's one of those times where you'd cock an eyebrow and say, "What in the world were they thinking?" The FTC has slapped them with accusations of misleading privacy claims...

York Space Systems Class Action: Deadline Approaches

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Chemours Faces Class Action Over Fraud Allegations

Chemours and the Aftermarket Mirage When it rains, it pours, and for Chemours, the forecast isn't looking sunny. Investors are gearing up to slap Chemours Company (NYSE: CC) with a securities fraud class action. Why, you ask? Overstatement of aftermarket demand for refrigerants left investors high and dry after stock prices took an 18% nosedive. On August 4, 2026,...

DigitalXForce Booms with 514% Growth and Major Backing

Massive Growth and Strategic Investment in DigitalXForce Now here’s a company that’s shaking things up—DigitalXForce. Right on the back of a staggering 514% growth, they’ve corralled a strategic investment from Arsenal Growth Equity. If you blink, you might miss just how fast they’re sprinting through the tech landscape. Institutional Support Backing the...

Think Together Marks 20 Years of ASES Impact in CA

Hands-on Learning: California's Bright Future Starts Here Who's ever thought a schoolyard's the same after three? Let me tell you, in California, it's staying alive and kicking, thanks to Think Together's whirlwind of celebrations for the After School Education and Safety (ASES) program. We're talking 450 schoolyard shindigs highlighting not just how far expanded learning...